Latest News & Updates

Breaking News

  • 18 hours ago

  • Team Pharma Now

BrandManthan 2025 Brings India’s Pharma Marketing Leaders Together for a High-Impact Strategy Summit in Mumbai
Breaking News
DISCO Pharmaceuticals Appoints Mark Manfredi, Ph.D., As CEO And Completes €36 Million Seed Financing To Advance Surfaceome-Targeted Cancer Pipeline

Simantini Singh Deo

Other trending news you may like to read

BrandManthan 2025 Brings India’s Pharma Marketing Leaders Together for a High-Impact Strategy Summit in Mumbai

BrandManthan 2025 returns to Mumbai on December 20, bringing pharma marketing leaders together to build compliant, patient-centric brands.

Team Pharma Now

Pharma Now

DISCO Pharmaceuticals Appoints Mark Manfredi, Ph.D., As CEO And Completes €36 Million Seed Financing To Advance Surfaceome-Targeted Cancer Pipeline

DISCO Pharmaceuticals appoints Mark Manfredi as CEO and secures €36M seed funding to advance its surfaceome-targeted ADC pipeline in SCLC and MSS-CRC.

Simantini Singh Deo

Pharma Now

OKYO Pharma Reports New Phase 2 Findings Showing Urcosimod 0.05% Reduces Pain And Improves Corneal Nerve Structure In Patients With Neuropathic Corneal Pain

OKYO Pharma’s Phase 2 trial shows urcosimod improves corneal nerve structure and reduces neuropathic corneal pain, strengthening its first-in-class treatment potential.

Simantini Singh Deo

Pharma Now

MAIA Biotechnology Doses First Patient In THIO-104 Phase 3 Trial Testing Ateganosine As A Third-Line Treatment For Advanced NSCLC

MAIA doses the first patient in its THIO-104 Phase 3 trial evaluating ateganosine plus CPI for advanced NSCLC, marking a key step toward potential FDA approval.

Simantini Singh Deo

Pharma Now